Results 251 to 260 of about 467,609 (357)

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

International Journal of Cancer, EarlyView.
What's New? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman, Niven Mehra, Laurien J. Zeverijn, Birgit S. Geurts, Karlijn Verkerk, Soemeya F. Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Addy C. M. van de Luijtgaarden, Theo van Voorthuizen, Tineke E. Buffart, Hans Gelderblom, Emile E. Voest, Henk M. W. Verheul   +15 more
wiley   +1 more source

Expression and prognostic significance of cathepsin D in acute myeloid leukemia. [PDF]

Medicine (Baltimore)
Han H, Huang Y, Xie J, Liu J, Wang W.
europepmc   +1 more source

Homoharringtonine suppresses acute myeloid leukemia progression by orchestrating EWSR1 phase separation in an m6A‐YTHDF2‐dependent mechanism

iMeta, EarlyView.
Homoharringtonine (HHT), a clinically approved anti‐leukemic drug, directly binds the RNA‐binding protein EWSR1. HHT induces an allosteric conformational switch in the RNA recognition motif of EWSR1, driving self‐association and liquid–liquid phase separation (LLPS). The resulting condensates act as regulatory hubs that sequester the m6A reader YTHDF2,
Ting‐Ting Liu, Li‐Ting Chen, Xu‐Ying Pei, Shao‐Nan Hu, Fang‐Fang Zhuo, Ze‐Kun Chen, Yang Liu, Jing‐Kang Wang, Ji‐Chao Zhang, Qi Cao, Ling Li, Jing Wang, Tian‐Tian Wei, Bo Han, Peng‐Fei Tu, Xiang‐Yu Zhao, Ruidong Xue, Ke‐Wu Zeng   +17 more
wiley   +1 more source

Role of Toll-Like Receptors in Myeloid Neoplasms: Focuses on the Molecular Mechanisms and Clinical Impact on Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myeloid Leukemia. [PDF]

APMIS
Cavalcante CBA, Chaves AC, de Oliveira VS, de Araújo MAS, Cunha E Silva TM, Goes JVC, de Oliveira RTG, Pinheiro RF, Ribeiro-Junior HL.   +8 more
europepmc   +1 more source

Genome‐wide CRISPR screen reveals an uncharacterized spliceosome regulator as new candidate immunotherapy target

iMeta, EarlyView.
This study identifies the uncharacterized gene C9ORF50 as a novel regulator of immune evasion. Functioning as an intrinsically disordered protein, C9ORF50 drives liquid‐liquid phase separation to facilitate spliceosome assembly and maintain RNA splicing fidelity.
Tong Shao, Chuanyang Liu, Jingyu Kuang, Sisi Xie, Ying Qu, Yingying Li, Lulu Zhang, Fangzhou Liu, Yanhua Qi, Tao Hou, Ming Li, Sujuan Zhang, Yu Liu, Zhixiang Yuan, Jiali Liu, Yanming Hu, Jingyang Wang, Chenghu Song, Shaowei Zhang, Lingyun Zhu, Jianzhong Shao, Aifu Lin, Wenjun Mao, Guangchuan Wang, Lvyun Zhu   +24 more
wiley   +1 more source

HLA diversity is associated with TKI response and treatment-free remission in chronic myeloid leukemia. [PDF]

Hemasphere
Toulemonde C, Dubois V, Bouvier C, Ridao A, Archier MC, Balsat M, Ducastelle S, Barraco F, Fossard G, Hildt J, Bollard J, Michallet M, Labussière-Wallet H, Hayette S, Nicolini FE, Alcazer V.   +15 more
europepmc   +1 more source

Most costly and prevalent reasons for hospitalization in children with medical complexity in Ontario, Canada

Journal of Hospital Medicine, EarlyView.
Abstract Background and Objectives Children with medical complexity (CMC) have chronic health conditions often associated with functional limitations. CMC comprise 1%–5% of the pediatric population. In Canada, their care accounts for one‐third of pediatric health spending.
Erin Hessey, Thaksha Thavam, Sanjay Mahant, Eyal Cohen, Jingqin Zhu, Francine Buchanan, Teresa To, Peter J. Gill, Ontario Pediatric Hospital Care Study Group (OPHCSG) and the Canadian Paediatric Inpatient Research Network (PIRN), Wenjia Chen, Ronald Cohn, Mairead Green, Matt Hall, Kate Langrish, Colin Macarthur, Myla Moretti, Patricia Parkin, Michelle Quinlan, Ann Bayliss, Ronik Kanani, Sean Murray, Catherine Pound, Mahmoud Sakran, Anupam Sehgal, Sepi Taheri, Gita Wahi   +25 more
wiley   +1 more source

Curcumin and Acute Myeloid Leukemia: Synergistic Effects with Targeted Therapy. [PDF]

Int J Mol Sci
Badagliacca R, Fazio M, Stagno F, Mirabile G, Gerace D, Allegra A.   +5 more
europepmc   +1 more source

Atypical Wounds in Chronic Graft‐Versus‐Host Disease and Peripheral Arterial Disease Caused by Tyrosine Kinase Inhibitors

JEADV Clinical Practice, EarlyView.
ABSTRACT The term “atypical wounds” primarily refers to lesions with immunological or cancerous etiologies. However, these wounds can also be drug‐induced. We report about a 32‐year‐old man with a 6‐year history of chronic myelogenous leukemia (CML) and chronic graft‐versus‐host disease (cGvHD) following an HLA‐compatible allogeneic stem cell ...
E. K. Stuermer, K. Malik, C. Willers, M. Augustin   +3 more
wiley   +1 more source

An Account of Acute Myeloid Leukemia Complicating Pregnancy and Literature Review. [PDF]

Diagnostics (Basel)
Nemeti G, Jimbu L, Mesaros O, Goidescu IG, Moisa C, Surcel M, Goidescu CM, Boitor-Borza D, Cruciat G, Rotar IC, Muresan D.   +10 more
europepmc   +1 more source